Submit Manuscript  

Article Details


Novel Biologics for the Treatment of Pediatric Severe Asthma

Author(s):

Amelia Licari, Riccardo Castagnoli, Enrico Tondina, Giorgia Testa, Giuseppe Fabio Parisi, Alessia Marseglia, Ilaria Brambilla and Gian Luigi Marseglia*   Pages 1 - 9 ( 9 )

Abstract:


Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

Keywords:

severe asthma, children, omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab

Affiliation:

S.C. Pediatria, Fondazione IRCCS Policlinico San Matteo, Pavia, Department of Pediatrics, University of Pavia, Department of Pediatrics, University of Pavia, S.C. Pediatria, Fondazione IRCCS Policlinico San Matteo, Pavia, Department of Clinical and Experimental Medicine, University of Catania, Department of Pediatrics, University of Pavia, S.C. Pediatria, Fondazione IRCCS Policlinico San Matteo, Pavia, S.C. Pediatria, Fondazione IRCCS Policlinico San Matteo, Pavia



Read Full-Text article